Amedisys (AMED) Misses Q3 EPS by 10c
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Interest expense: -1.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Interest expense: -1.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.98, $0.10 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $556.24 million versus the consensus estimate of $560.59 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Champions Oncology (CSBR) Tops Q1 EPS by 6c
- Cosciens acquires Nualtis for up to $15M in cash deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
